(Q44340139)

2 December 2017

title

A micro opioid receptor gene polymorphism (A118G) and naltrexone treatment response in adherent Korean alcohol-dependent patients (English)

1 reference

2 December 2017

0 references

0 references

11

David W Oslin

1 reference

2 December 2017

Sung-Gon Kim

1

1 reference

2 December 2017

Cheol-Min Kim

2

1 reference

2 December 2017

Sam-Wook Choi

3

1 reference

2 December 2017

Young-Myo Jae

4

1 reference

2 December 2017

Hae-Gook Lee

5

1 reference

2 December 2017

Bong-Ki Son

6

1 reference

2 December 2017

Jeong-Gee Kim

7

1 reference

2 December 2017

Young-Sung Choi

8

1 reference

2 December 2017

Han-Oh Kim

9

1 reference

2 December 2017

Seong-Yeon Kim

10

1 reference

2 December 2017

publication date

16 September 2008

1 reference

2 December 2017

number of pages

8

1 reference

inferred from page(s)

published in

Psychopharmacology

1 reference

2 December 2017

volume

201

1 reference

2 December 2017

issue

4

1 reference

2 December 2017

page(s)

611-618

1 reference

Implications of endogenous opioids and dopamine in alcoholism: human and basic science studies

2 December 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00213-008-1330-5

Naltrexone in the treatment of alcohol dependence

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00213-008-1330-5

Effect of naltrexone on alcohol "high" in alcoholics

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00213-008-1330-5

Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study

21 January 2018

1 reference

https://pubmed.ncbi.nlm.nih.gov/18795264

12 December 2020

The polymorphism A118G of the human mu-opioid receptor gene decreases the pupil constrictory effect of morphine-6-glucuronide but not that of morphine

1 reference

https://pubmed.ncbi.nlm.nih.gov/18795264

12 December 2020

Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18795264

12 December 2020

Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction

1 reference

https://pubmed.ncbi.nlm.nih.gov/18795264

12 December 2020

Genetics of two mu opioid receptor gene (OPRM1) exon I polymorphisms: population studies, and allele frequencies in alcohol- and drug-dependent subjects

1 reference

https://pubmed.ncbi.nlm.nih.gov/18795264

12 December 2020

Effect of naltrexone on subjective alcohol response in subjects at high and low risk for future alcohol dependence

1 reference

https://pubmed.ncbi.nlm.nih.gov/18795264

12 December 2020

Naltrexone and cue exposure with coping and communication skills training for alcoholics: treatment process and 1-year outcomes

1 reference

https://pubmed.ncbi.nlm.nih.gov/18795264

12 December 2020

Association of mu-opioid receptor gene polymorphism (A118G) with variations in morphine consumption for analgesia after total knee arthroplasty

1 reference

https://pubmed.ncbi.nlm.nih.gov/18795264

12 December 2020

Differential neural response to alcohol priming and alcohol taste cues is associated with DRD4 VNTR and OPRM1 genotypes

1 reference

https://pubmed.ncbi.nlm.nih.gov/18795264

12 December 2020

A polymorphism of the mu-opioid receptor gene (OPRM1) and sensitivity to the effects of alcohol in humans

1 reference

https://pubmed.ncbi.nlm.nih.gov/18795264

12 December 2020

An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study

1 reference

https://pubmed.ncbi.nlm.nih.gov/18795264

12 December 2020

Naltrexone for alcohol dependence: a randomized controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/18795264

12 December 2020

Naltrexone as an adjunctive treatment for older patients with alcohol dependence

1 reference

https://pubmed.ncbi.nlm.nih.gov/18795264

12 December 2020

A functional polymorphism of the mu-opioid receptor gene (OPRM1) influences cue-induced craving for alcohol in male heavy drinkers.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18795264

12 December 2020

Human mu-opioid receptor variation and alcohol dependence

1 reference

https://pubmed.ncbi.nlm.nih.gov/18795264

12 December 2020

Mu opioid receptor gene variants: lack of association with alcohol dependence

1 reference

https://pubmed.ncbi.nlm.nih.gov/18795264

12 December 2020

The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/18795264

12 December 2020

Predicting treatment response to naltrexone: the influence of craving and family history

1 reference

https://pubmed.ncbi.nlm.nih.gov/18795264

12 December 2020

Association between the cortisol response to opioid blockade and the Asn40Asp polymorphism at the mu-opioid receptor locus (OPRM1).

1 reference

https://pubmed.ncbi.nlm.nih.gov/18795264

12 December 2020

Association of the mu-opioid receptor gene with smoking cessation

1 reference

https://pubmed.ncbi.nlm.nih.gov/18795264

12 December 2020

The mu-opioid receptor gene polymorphism (A118G) alters HPA axis activation induced by opioid receptor blockade

1 reference

https://pubmed.ncbi.nlm.nih.gov/18795264

12 December 2020

Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/18795264

12 December 2020

Naltrexone and coping skills therapy for alcohol dependence. A controlled study

1 reference

https://pubmed.ncbi.nlm.nih.gov/18795264

12 December 2020

Association of functional opioid receptor genotypes with alcohol dependence in Koreans

1 reference

https://pubmed.ncbi.nlm.nih.gov/18795264

12 December 2020

Posttreatment results of combining naltrexone with cognitive-behavior therapy for the treatment of alcoholism

1 reference

https://pubmed.ncbi.nlm.nih.gov/18795264

12 December 2020

The mu-opioid receptor gene polymorphism 118A>G depletes alfentanil-induced analgesia and protects against respiratory depression in homozygous carriers

1 reference

https://pubmed.ncbi.nlm.nih.gov/18795264

12 December 2020

Naltrexone vs. nefazodone for treatment of alcohol dependence. A placebo-controlled trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18795264

12 December 2020

DNA isolation by a rapid method from human blood samples: effects of MgCl2, EDTA, storage time, and temperature on DNA yield and quality

1 reference

https://pubmed.ncbi.nlm.nih.gov/18795264

12 December 2020

The 118 A > G polymorphism in the human mu-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/18795264

12 December 2020

The human mu-opioid receptor gene polymorphism 118A > G decreases cortical activation in response to specific nociceptive stimulation

1 reference

https://pubmed.ncbi.nlm.nih.gov/18795264

12 December 2020

Acute and chronic ethanol treatment on beta-endorphin and catecholamine levels

1 reference

https://pubmed.ncbi.nlm.nih.gov/18795264

12 December 2020

A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/18795264

12 December 2020

The effect of naltrexone and acamprosate on cue-induced craving, autonomic nervous system and neuroendocrine reactions to alcohol-related cues in alcoholics.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18795264

12 December 2020

Multiple opiate receptors: Support for unique mu, delta and kappa sites

1 reference

https://pubmed.ncbi.nlm.nih.gov/18795264

12 December 2020

Ethanol-induced increase in endogenous dopamine release may involve endogenous opiates

1 reference

https://pubmed.ncbi.nlm.nih.gov/18795264

12 December 2020

Family history and antisocial traits moderate naltrexone's effects on heavy drinking in alcoholics

1 reference

https://pubmed.ncbi.nlm.nih.gov/18795264

12 December 2020

The role of neurotransmitters in alcohol dependence: animal research

1 reference

https://pubmed.ncbi.nlm.nih.gov/18795264

12 December 2020

Naltrexone in the treatment of alcohol dependence

1 reference

https://pubmed.ncbi.nlm.nih.gov/18795264

12 December 2020

A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse

1 reference

https://pubmed.ncbi.nlm.nih.gov/18795264

12 December 2020

Effect of mu-opioid receptor gene polymorphisms on heroin-induced subjective responses in a Chinese population

1 reference

https://pubmed.ncbi.nlm.nih.gov/18795264

12 December 2020

Association of OPRM1 A118G variant with the relative reinforcing value of nicotine.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18795264

12 December 2020

10.1007/S00213-008-1330-5

Identifiers

DOI

1 reference

2 December 2017

1 reference